Literature DB >> 2841247

DNA blotting analysis of human retroviruses in cerebrospinal fluid of spastic paraparesis patients: the viruses are identical to human T-cell leukemia virus type-1 (HTLV-1).

J Imamura1, A Tsujimoto, Y Ohta, S Hirose, K Shimotohno, M Miwa, I Miyoshi.   

Abstract

The structure of the integrated provirus in cell lines established from the cerebrospinal fluid (CSF) of patients with human T-cell leukemia virus type-1 (HTLV-1)-associated myelopathy (HAM) was analyzed. The digestion patterns with 3 restriction endonucleases, Sac I, Eco RI and PstI, of the proviruses integrated in T-lymphoid cell lines derived from the CSF of 4 HAM patients were similar to those of HTLV-1 from adult T-cell leukemia (ATL) patients. Integrated proviruses in one of these cell lines derived from the CSF were further analyzed in detail with 2 more restriction enzymes, BamHI and Sma I. The results indicate that the retrovirus found in lymphocytes of the CSF from patients with HAM are very similar, if not identical, to HTLV-1 found in the leukemic lymphocytes of ATL patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2841247     DOI: 10.1002/ijc.2910420213

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

Review 1.  The epidemiology of HTLV-I infection.

Authors:  N Mueller
Journal:  Cancer Causes Control       Date:  1991-01       Impact factor: 2.506

2.  Characterization of two human lymphoid cell lines producing human T-lymphotropic virus type I (HTLV-I) isolated from patients with HTLV-I-associated myelopathy or encephalopathy.

Authors:  J Iwata; T Oka; M Furihata; H Sonobe; K Matsubayashi; Y Uemura; I Miyoshi; Y Ohtsuki
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

3.  Chimeric matrix proteins encoded by defective proviruses with large internal deletions in human T-cell leukemia virus type 1-infected humans.

Authors:  V A Morozov; S Lagaye; G P Taylor; E Matutes; R A Weiss
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.